Recruiting
Phase 2

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04550481

Conditions

Hepatocellular Carcinoma

Nonalcoholic Steatohepatitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Lisinopril

Liver Ultrasonographic Elastography

Magnetic Resonance Elastography

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information